Iranian Scientists Produce Engineered Oncolytic Virus for Treatment of Glioblastoma Cancer
The main focus of the company is on the design and manipulation of vectors and viruses. By providing advanced GLP and GMP infrastructure and the presence of a team of experienced researchers, the complex is able to complete the full cycle of biological and biotechnological product production from zero to one hundred; from proposal and vector design to vector production, conducting cellular and animal experiments, and finally making the final product.
“Our product has been manufactured in three series and all of its preclinical stages have been completed. We are currently compiling documentation to obtain approval from the Food and Drug Administration of Iran and will soon enter the clinical phases,” said Massoumeh Alamdar, the production manager and a research team member of the knowledge-based company.
“Our product is used to treat glioblastoma cancer. It is actually an engineered oncolytic virus that, through genetic changes and manipulations, has been transformed into a form that enjoys the capability to target and destroy cancer cells. The technical and research stages of this product have been completed and we are now preparing its documentation,” she added.
An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour.
Oncolytic viruses are thought not only to cause direct destruction of the tumour cells, but also to stimulate host anti-tumour immune system responses.
Oncolytic viruses also have the ability to affect the tumor micro-environment in multiple ways.
4155/v
